Search

everythinglearnresearchcommunity

for

Search:↓

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.

Skin problems in the elderly are unique and may indicate other diseases, involving changes in skin, hair, nails, and increased cancer risk.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

Steroid hormones are crucial for body functions and have various medical uses, but their misuse can lead to dependence.

Flaxseed lignans may reduce breast cancer risk in women.

Estrogens can improve skin aging but carry risks; more research is needed on safer treatments.

Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

Estrogens generally inhibit hair growth and improve skin quality, but their exact effects on hair follicles are complex and not fully understood.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Steroid-producing capabilities in certain cancers may contribute to treatment resistance.

Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.

Anabolic androgenic steroids can increase cancer risk and disrupt hormones.

A man with a rare adrenal cancer showed unusual symptoms and died four months after diagnosis.

Treating hirsutism in women often requires a mix of medications and cosmetic methods for best results.

A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.

A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

Early hormones shape sex-specific differences in rat glands.

RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.

Both estrogens and androgens are important for health in both males and females.

Glibenclamide slows breast cancer cell growth by stopping cell division.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.